SLF
TVTX icon

Sun Life Financial’s Travere Therapeutics TVTX Stock Holding History

Sun Life Financial’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,732
Closed -$66K – 574
2019
Q3 		$66K Buy
+5,732
New +$94.7K 0.02% 270

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sun Life Financial's TVTX Position: Q4 2019 in Review

Sun Life Financial sold out of Travere Therapeutics (TVTX) in Q4 2019, closing a stake of 5,732 shares — an estimated $66K sold.

Sun Life Financial first reported a position in TVTX in Q3 2019 and held it in 1 quarter. The position peaked at $66K in Q3 2019. 131 funds tracked by Wall St. Rank hold TVTX as of Q4 2019.

  • Sun Life Financial reported no remaining Travere Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Sun Life Financial sold 5,732 Travere Therapeutics shares in Q4 2019, an estimated $66K.
  • Sun Life Financial first reported a position in Travere Therapeutics in Q3 2019 and held it in 1 quarter.
  • Sun Life Financial's Travere Therapeutics position peaked at $66K in Q3 2019.
  • 131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2019.

Based on Sun Life Financial's 13F filing for Q4 2019, filed 10 Feb 2020.